MX2021010857A - Anticuerpos biespecificos anti-v(beta17)/anti-cd123. - Google Patents

Anticuerpos biespecificos anti-v(beta17)/anti-cd123.

Info

Publication number
MX2021010857A
MX2021010857A MX2021010857A MX2021010857A MX2021010857A MX 2021010857 A MX2021010857 A MX 2021010857A MX 2021010857 A MX2021010857 A MX 2021010857A MX 2021010857 A MX2021010857 A MX 2021010857A MX 2021010857 A MX2021010857 A MX 2021010857A
Authority
MX
Mexico
Prior art keywords
bispecific antibodies
beta17
antibodies
kasumi
pathologies
Prior art date
Application number
MX2021010857A
Other languages
English (en)
Inventor
Rajkumar Ganesan
Iqbal S Grewal
Manuel Alejandro Sepulveda
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2021010857A publication Critical patent/MX2021010857A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen anticuerpos biespecíficos anti-Vß17/anti-CD123 o fragmentos de unión al antígeno de estos; también se describen ácidos nucleicos que codifican los anticuerpos, 5 composiciones que comprenden los anticuerpos, métodos para producir los anticuerpos y métodos para usar los anticuerpos.
MX2021010857A 2019-03-11 2020-03-11 Anticuerpos biespecificos anti-v(beta17)/anti-cd123. MX2021010857A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962816464P 2019-03-11 2019-03-11
PCT/IB2020/000342 WO2020183245A2 (en) 2019-03-11 2020-03-11 ANTI-Vβ17/ANTI-CD123 BISPECIFIC ANTIBODIES

Publications (1)

Publication Number Publication Date
MX2021010857A true MX2021010857A (es) 2021-12-15

Family

ID=71670296

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010857A MX2021010857A (es) 2019-03-11 2020-03-11 Anticuerpos biespecificos anti-v(beta17)/anti-cd123.

Country Status (12)

Country Link
US (1) US20220127359A1 (es)
EP (1) EP3937977A2 (es)
JP (1) JP2022523442A (es)
KR (1) KR20210138033A (es)
CN (1) CN113874400A (es)
AU (1) AU2020235475A1 (es)
BR (1) BR112021017801A2 (es)
CA (1) CA3132916A1 (es)
IL (1) IL286147A (es)
MA (1) MA55305A (es)
MX (1) MX2021010857A (es)
WO (1) WO2020183245A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
UY39373A (es) * 2020-08-10 2022-02-25 Janssen Biotech Inc Materiales y métodos para producir linfocitos específicos de virus diseñados mediante bioingeniería
AU2021339754A1 (en) 2020-09-11 2023-05-25 Janssen Biotech, Inc. Methods and compositions for modulating beta chain mediated immunity
CA3194752A1 (en) * 2020-09-11 2022-03-17 Janssen Biotech, Inc. Multi-specific immune targeting molecules and uses thereof
CA3237038A1 (en) * 2021-11-01 2023-05-04 Janssen Biotech, Inc. Compositions and methods for the modulation of beta chain-mediated immunity
WO2023152633A1 (en) * 2022-02-09 2023-08-17 Janssen Biotech, Inc. Methods and compositions comprising v beta 17 bispecific t cell engagers and bioengineered virus specific lymphocytes

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6084087A (en) * 1991-09-27 2000-07-04 New York Society For The Ruptured And Crippled Maintaing The Hospital For Special Surgery DNA encoding conserved T-cell receptor sequences
DK1015576T3 (da) 1997-09-16 2005-08-29 Egea Biosciences Llc Fremgangsmåde til fuldstændig kemisk syntese og aggregering af gener og genomer
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
CA2759233C (en) 2009-04-27 2019-07-16 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
KR102152109B1 (ko) 2010-04-20 2020-09-07 젠맵 에이/에스 이종이량체 항체 ｆｃ-함유 단백질 및 그의 생산 방법
JP6167040B2 (ja) 2010-11-05 2017-07-19 ザイムワークス，インコーポレイテッド Ｆｃドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
MX358862B (es) 2011-11-04 2018-09-06 Zymeworks Inc Diseño de anticuerpo heterodimérico estable con mutaciones en el domino fc.
WO2013131001A1 (en) * 2012-03-02 2013-09-06 Academia Sinica ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF
ME03724B (me) * 2014-09-05 2021-01-20 Janssen Pharmaceutica Nv Agensi koji vezuju cd123 i njihove upotrebe
TWI790206B (zh) * 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
CN111344303A (zh) * 2017-06-01 2020-06-26 Xencor股份有限公司 结合cd123和cd3的双特异性抗体

Also Published As

Publication number Publication date
BR112021017801A2 (pt) 2022-01-18
CA3132916A1 (en) 2020-09-17
KR20210138033A (ko) 2021-11-18
WO2020183245A2 (en) 2020-09-17
AU2020235475A1 (en) 2021-09-30
US20220127359A1 (en) 2022-04-28
IL286147A (en) 2021-10-31
WO2020183245A3 (en) 2020-12-03
MA55305A (fr) 2022-01-19
CN113874400A (zh) 2021-12-31
EP3937977A2 (en) 2022-01-19
JP2022523442A (ja) 2022-04-22

Similar Documents

Publication Publication Date Title
MX2021010857A (es) Anticuerpos biespecificos anti-v(beta17)/anti-cd123.
ZA202102549B (en) Substituted tolyl as fungicides
CL2020000595S1 (es) Estuche de auriculares.
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
IL277072A (en) Anti-claudin antibodies 18.2
EP3821566A4 (en) DETERMINING THE MOST LIKELY CAUSE OF TELECOMMUNICATIONS EVENTS
EA201890158A1 (ru) Антитела против ntb-a и связанные композиции и способы
NZ736728A (en) Cd123 antibodies and conjugates thereof
MX2017006530A (es) Nuevos peptidos que se unen al ligando-1 de muerte programada (pd-l1) para formacion de imagen.
MX2020003497A (es) Metodo para generar anticuerpos multiespecificos a partir de anticuerpos monoespecificos.
IL290267A (en) Bispecific antibodies are directed against cd3
PH12020500341A1 (en) Pentacyclic compound
EP3917969A4 (en) NEW BISPECIFIC CD3/CD20 POLYPEPTIDIC COMPLEXES
CL2020001201S1 (es) Automóvil.
CL2020000174S1 (es) Automóvil.
IL286757A (en) Antibodies in specific
MX2021000797A (es) Anticuerpos agonistas de cd226.
IL276211A (en) Process for producing hu14.18k322a monoclonal antibody
CL2019001469S1 (es) Cepillo de dientes.
ZA202109785B (en) Immunosensor
CL2019001470S1 (es) Cepillo de dientes.
CL2020000224S1 (es) Automóvil.
CL2019001123S1 (es) Cepillo de dientes.
EP3841243A4 (en) SYNTHETIC LEATHER FORMING PROCESS
CA187928S (en) Chain for eyeglasses